Fosså S D, de Garis S T, Heier M S, Flokkmann A, Lien H H, Salveson A, Moe B
Cancer. 1986 Apr 15;57(8 Suppl):1700-4. doi: 10.1002/1097-0142(19860415)57:8+<1700::aid-cncr2820571313>3.0.co;2-b.
Twenty patients with measurable metastatic renal cell carcinoma (RCC) were were treated with interferon alfa-2a (Roferon-A), 36 X 10(6)U intramuscularly 3 times weekly, alone (2 patients) or in combination with vinblastine, 0.10-0.15 mg/kg intravenously every 2 to 3 weeks. Objective responses in the lung, bone, liver, and lymph node metastases were seen in 6 of 18 evaluable patients. Dose reduction of interferon alfa-2a was necessary in 19 of the 20 patients due to intolerable flu-like side effects and fatigue. Bone marrow suppression and increase of gamma-GT represented the most often observed objective toxicity. The preliminary results of this combination treatment in RCC are promising and warrant randomized studies exploring the role of vinblastine. The dose of interferon alfa-2a should be reduced by 50% to avoid excessive toxicity and to maximize patient compliance.
20例有可测量转移性肾细胞癌（RCC）的患者接受了α-2a干扰素（罗扰素）治疗，每周3次，每次36×10⁶U肌肉注射，单独治疗（2例患者）或与长春花碱联合使用，每2至3周静脉注射0.10 - 0.15mg/kg。18例可评估患者中有6例在肺、骨、肝和淋巴结转移灶出现客观缓解。由于难以耐受的流感样副作用和疲劳，20例患者中有19例需要减少α-2a干扰素的剂量。骨髓抑制和γ-GT升高是最常观察到的客观毒性反应。这种联合治疗RCC的初步结果很有前景，值得进行随机研究以探索长春花碱的作用。α-2a干扰素的剂量应减少50%，以避免过度毒性并最大限度地提高患者依从性。
Zotero 插件